COVID-19: The Ivermectin African Enigma
Abstract
Introduction: The low frequency of cases and deaths from the SARS-CoV-2 COVID-19 virus in some countries of Africa has called our attention to the unusual behavior of this disease.
Aims: Describe SARS-CoV2 infection and death rates in African countries that participated in an intensive Ivermectin mass campaign carried out to control onchocerciasis and compare them with those of countries that did not participate.
Methods: Data from 19 countries that participated in the WHO sponsored African Programme for Onchocerciasis Control (APOC), from 1995 until 2015, intended to treat over 90 million people annually and protect an at-risk population of 115 million, were compared with thirty-five (Non-APOC), countries that were not included. Information was obtained from https://www.worldometers.info/coronavirus/ database.
Results After controlling for different factors including the Human Development Index, APOC countries, show statistically significant 28% lower mortality (0.72 IC 95% 0,67-0,78) and 8% lower rate of infection (0.92 IC95% 0,91-0,93) due to COVID-19.
Conclusions: The incidence in mortality rates and the number of cases is significantly lower among the APOC countries compared to non-APOC countries. That a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use is an attractive hypothesis. Additional studies are needed to confirm it.
Authors
Downloads
Keywords
- Onchocerciasis
- Ivermectin
- Elephantiasis, Filaria
- Albendazole
- Confounding Factors, Epidemiologic
- COVID-19
- Life Expectancy
- Onchocerciasis, Ocular
- Severe Acute Respiratory Syndrome
- coronavirus 2
- Coronavirus Infections
Author Biographies
, Universidad del Valle, Instituto de Investigación y Desarrollo en Prevención de la Violencia y Promoción de la Convivencia Social, CISALVA, Cali, Colombia., Colombia
https://orcid.org/0000-0002-4683-7987
, Universidad del Valle, Facultad de Salud, Escuela de Medicina, Departamento de Patología, Cali, Colombia, Colombia Registro Poblacional de Cáncer, Cali, Colombia., Colombia
, Universidad del Valle, Facultad de Salud, Doctorado en Salud, Cali, Colombia., Colombia
References
WHO/APOC. The WHO African Programme for Onchocerciasis Control Final Evaluation Report [Internet]. 2015. Available from: www.who.int/apoc
Merck Sharp & Dohme Corp. Over 30 Years: The Mectizan® Donation Program [Internet]. 2019 [cited 2020 Aug 5]. p. 6-11. Available from: https://www.merck.com/stories/mectizan/
Sodahlon Y. Mectizan Donation Program. 2019 Annual Highlights [Internet]. Celebrating Milestones & Looking to the Future. 2019 [cited 2020 Aug 5]. p. 1-20. Available from: https://mectizan.org/wp-content/uploads/2020/06/MDP_AH19_051920.pdf
Worldometer. Coronavirus Update (Live): Cases and Deaths from COVID-19 Virus Pandemic [Internet]. Worldometers. 2020. p. 1. Available from: https://www.worldometers.info/coronavirus/%0Ahttps://www.worldometers.info/coronavirus/?
World Bank Group. Population , total - South Africa [Internet]. Vol. 19. 2020. p. 1-18. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL?locations=ZA
R Core Team. R: A language and environment for statistical computing. [Internet]. Vienna Austria; 2020. Available from: https://www.r-project.org/
HDR. Human Development Report 2019: beyond income, beyond averages, beyond today: Inequalities in human development in the 21st century [Internet]. United Nations Development Program. 2019. Available from: http://hdr.undp.org/sites/default/files/hdr2019.pdf
Norrestad F. Number of coronavirus tests in Iceland 2020 [Internet]. Oct 20, 2020. Available from: https://www.statista.com/statistics/1106855/tested-and-confirmed-coronavirus-cases-in-iceland/
World Health Organization. WHO methods and data sources for country-level causes of death 2000-2016 [Internet]. World Health Organization. 2018. Available from: http://hdr.undp.org/sites/default/files/hdr2019.pdf
World Health Organization. WHO methods and data sources for country-level causes of death 2000-2015 [Internet]. 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25378742%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4221770
Liu K, He M, Zhuang Z, He D, Li H. Unexpected positive correlation between human development index and risk of infections and deaths of COVID-19 in Italy. One Heal [Internet]. 2020;10(September):1-3. Available from: https://reader.elsevier.com/reader/sd/pii/S2352771420302755?token=4F114E6CAAC56546D45EF8E0C4D7CB1A18E05F165E3FE295C311ABA2F6E870ACA163E4689383E234F4DF48BEE87E6AD4
Shahbazi F, Khazaei S. Socio-economic inequality in global incidence and mortality rates from coronavirus disease 2019: an ecological study. New Microbes New Infect [Internet]. 2020;38:100762. Available from: https://doi.org/10.1016/j.nmni.2020.100762
Mbow M, Lell B, Jochems SP, Cisse B, Mboup S, Dewals BG, et al. COVID-19 in Africa: Dampening the storm? Science (80- ). 2020;369(6504):624-6. https://doi.org/10.1126/science.abd3902
Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res J [Internet]. 2020;178-104787(March):1-4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/pdf/main.pdf. https://doi.org/10.1016/j.antiviral.2020.104787
Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies [Internet]. 2020. Available from: https://www.researchsquare.com/article/rs-73308/v1. https://doi.org/10.21203/rs.3.rs-73308/v1
Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob [Internet]. 2020;19(1):1-5. Available from: https://doi.org/10.1186/s12941-020-00368-w
Varghese FS, Kaukinen P, Gläsker S, Bespalov M, Hanski L, Wennerberg K, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res. 2016;126:117-24. https://doi.org/10.1016/j.antiviral.2015.12.012
Cepelowicz J-R, Sherman M, Fatteh N, Voge F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv [Internet]. 2020;19. Available from: https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2.article-info
Shouman W. Prophylactic Ivermectin in COVID-19 Contacts [Internet]. https://clinicaltrials.gov/show/NCT04422561. 2020. p. 1-5. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118717/full
Jans D, Wagstaff K. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells [Internet]. 2020;2100(9):52-3. Available from: www.mdpi.com/journal/cells. https://doi.org/10.3390/cells9092100
Copyright (c) 2020 Universidad del Valle
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use
